Nov 10 (Reuters) - Novo Nordisk has partnered

with India's Emcure Pharmaceuticals to exclusively

distribute and market its weight-loss drug under a new brand in

the country, the companies said on Monday.

Under the agreement, the Danish drugmaker will sell Poviztra

2.4 milligram (mg) semaglutide injection in India as a separate

brand of its blockbuster weight-loss treatment Wegovy.

Shares of Emcure Pharma rose following the announcement,

trading 6.5% higher at 1,451 rupees.

Novo Nordisk launched Wegovy in India in June, three months

after Eli Lilly ( LLY ) introduced its competing weight-loss

product Mounjaro in the world's most populous nation.

Wegovy's 2.4 mg dose is priced at 26,015 rupees for a

month's supply in India, while pricing for Poviztra was not

disclosed.

"This partnership is part of Novo Nordisk India's efforts to

ensure its innovative treatments reach a greater number of

patients in India," the Danish company said in an exchange

filing.

Last month, Eli Lilly ( LLY ) also partnered with Cipla to

sell its weight-loss drug under a separate brand in India.